From:  The role of eosinophils in the management of acute paediatric wheeze: a scoping review

 Summary of large paediatric data sets providing eosinophil values for children.

Author/yearPopulation/sampling pointCountry/study designEosinophil values (× 109/L)Eosinophil observations
Fitzpatrick et al. 2016 [20]n = 300
Age: 12–59 months
Timing: > 2 weeks after SCS		USA
Clinical trial		Mean = 0.26BEO > 0.3 × 109/L predictor of ICS response
Fitzpatrick et al. 2023 [21]n = 1,074
Age: 12–71 months
Timing: > 4 weeks after SCS		USA
3 clinical trials		Median = 0.24BEO significantly higher in males and children > 36 months
BEO a predictor of exacerbation rates
Just et al. 2021 [22]n = 402
Age = 1–15 years
Timing: no current SCS treatment		France
Cohort study		Mean 0.33
Q3 0.32 preschool age
Q3 0.60 school-age		BEO vary with age and gender
BEO associated with recurrent wheeze
Hartl et al. 2020 [23]n = 1,204
Age 6–18 years
Timing: unknown		Austrian
Cohort study		Median < 10 years
Female 0.18, male 0.24
Median 10–18 years
Female 0.12, male 0.16		BEO age and sex dependent with a plateau around puberty
Return to article view

Q3: upper limit of third quartile of age group. BEO: blood eosinophils, data reported to 2 dp; ICS: inhaled corticosteroid; SCS: systemic corticosteroids.